Lauren Sciences LLC @LaurenSciences

Lauren Sciences CEO Rosenbaum Invited Speaker at Drug Delivery Summit 2020 Lauren Sciences CEO Rosenbaum speaks on “V-Smart®: Non-Invasive Dual-Targeted BBB Delivery Solution for Non-Brain Penetrant CNS Therapeutic Agents” 12/15, Drug Delivery Summit. ddfsummit.com

Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum invited to speak on “V-Smart®: Non-Invasive, Dual-Targeted Delivery of Non-BBB Penetrant Therapeutic Agents to CNS” on Wednesday, September 2, 4:00 P.M., at virtual Blood-Brain Barrier Summit 2020. bbbsummit.com

Lauren Sciences CEO Susan Rosenbaum interviewed by Proactive Investors at BIO CEO & Investor Conference, NY, February 11, 2020. See interview, “Lauren Sciences wins 4th grant for its ALS drug”: proactiveinvestors.co.uk/companies/news…

Lauren Sciences Wins to Present at 2020 BIO CEO & Investor Conference Lauren Sciences' Founder, Chairman & CEO Rosenbaum at 2020 BIO CEO & Investor Conference, Feb.10-11, 2020, presents Tues., Feb. 11, 9AM. bio.org/events/bio-ceo….

China Focus announced that Lauren Sciences won First Place in Global Healthcare Innovation Competition at BIO 2019 in Philadelphia, PA in June. laurensciencesllc.com/newsroom/in-th…

Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum invited to speak on “Developing Non-Invasive, Dual-Targeted Brain Therapeutics for CNS Diseases Using V-Smart® Platform Technology” on Thursday, August 15, 10:45 A.M., at Blood-Brain Barrier Drug Delivery 2019, Boston, MA.

Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum invited speaker on V-Smart® Nanomedicine for GBM @ 3:25 P.M., “Novel Applications and Treatments for Malignant Glioma” session, Brain Tumor Biotech Summit 2019, June 7, New York, NY. northwellhealth.org/2XTQ-UZ4G-BF6K…

Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum invited to speak on V-Smart® Nanomedicines for “Parkinson’s and Other Movement Disorders” @ 2:00 P.M on May 22, Neurotech Conference, May 21-22, 2019, Boston, MA. Meet with us there -- next.brella.io/events.

Lauren Sciences LLC wins AU $1Million Grant Award from FightMND. eurekalert.org/pub_releases/2…

Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum invited to present Lauren Sciences LLC, a BIO International 2018 winner, at BIO Investor Forum, CNS/Neurological track, October 17-18, 2018, San Francisco, California. Please schedule meeting us partnering.bio.org/bif2018

Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum invited to present talk on, “V-Smart® Nanomedicine Platform Technology: Non-invasive, Targeted Brain Delivery of Non-Brain Penetrant Agents for Treatment of CNS Diseases”, to NIH and DOD on August 21-22, 2018.

Lauren Sciences Winner at BIO: BIO, biotechnology industry’s leading organization, announces Lauren Sciences as one of the winners at forum held during BIO’s 25th International Convention in June in Boston, MA. bio.org/press-release/…

Lauren Sciences Develops First V-Smart®-Antibody: Preliminary data presented in Poster 150 at Controlled Release Society (CRS) 2018 Annual Meeting, New York, 5:00 - 6:00 PM, Monday, July 23 and 12:30-1:30 PM, Tuesday, July 24.

Lauren-Sciences-Logo-01.png Lauren Sciences Founder, Chairman & CEO Susan Rosenbaum to present keynote address, “V-Smart® Nanomedicines: Non-Invasive Targeted Therapeutics for Brain Diseases”, 4th Annual Formulation & Drug Delivery Congress, May 8-9, 2018, London, UK.

Lauren Sciences LLC, a private biotechnology company, recently received a third grant from The ALS Association to support the continued development of LAUR-301, its novel V-Smart Nanomedicine designed specifically for #ALS. Read more: bit.ly/2JY49Ro #MND #ALSResearch

Lauren Sciences LLC announces third grant award from The ALS Association (ALSA) to support continued development of LAUR-301, its novel V-Smart® Nanomedicine for ALS.  eurekalert.org/pub_releases/2…

This impt article from 6 months ago showed that the CDC Registry only found 57% of ppl w ALS that smaller studies had found. And the 43% it didn't find don't look like the folks it did! See the prob??? tandfonline.com/doi/full/10.10… 2/2

Lauren Sciences poster at 2017 Society for Neuroscience, D.C.

Lauren Sciences LLC is invited to present Poster 670.03, W11, entitled, “V-Smart® Nanomedicine for the Treatment of ALS (LAUR-301): Non-Invasive Targeted Delivery of GDNF to Degenerating Motoneurons in ALS”, at Society for Neuroscience (SfN) 2017 Annual Meeting, in D.C. on Nov 15

2017 BIO Investor Forum